Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended																6 Months Ended	12 Months Ended
	Dec. 31, 2018		Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Dec. 31, 2017		Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Data (Unaudited) [Abstract]
Revenue	$ 192,113		$ 145,395		$ 117,747		$ 144,419		$ 167,792		$ 118,314		$ 112,273		$ 115,800
Operating expenses	181,331		163,967		168,028		147,720		173,992		107,002		105,823		96,315			$ 661,046	$ 483,132	$ 392,936
Income (loss) from operations	10,782		(18,572)		(50,281)		(3,301)		(6,200)		11,312		6,450		19,485			(61,372)	31,047	(20,160)
Net income (loss)	302,735		(20,365)		(56,573)		(10,812)		(9,169)		(7,493)		(3,085)		8,964			214,985	(10,783)	(60,400)
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders	$ 320,078		$ (4,559)		$ (40,358)		$ (1,420)		$ (2,922)		$ (2,611)		$ (3,085)		$ 8,964			$ 273,741	$ 346	$ (60,400)
Basic net income (loss) per share (in dollars per share)	$ 2.32	[1],[2]	$ (0.03)	[1],[2]	$ (0.29)	[1],[2]	$ (0.01)	[1],[2]	$ (0.03)	[1],[2]	$ (0.02)	[1],[2],[3]	$ (0.02)	[2]	$ 0.07	[2]		$ 2.09	$ 0.15	$ (0.50)
Diluted net income (loss) per share (in dollars per share)	$ 2.21	[2],[4]	$ (0.03)	[2]	$ (0.29)	[2]	$ (0.01)	[2]	$ (0.03)	[2]	$ (0.02)	[2],[3]	$ (0.02)	[2]	$ 0.07	[2],[5],[6]		$ 2.07	$ 0.15	$ (0.50)
Income (Numerator) [Abstract]
Income (loss) available to Ionis common stockholders	$ 319,694		$ (4,563)		$ (37,932)		$ (1,212)		$ (3,124)		$ (1,976)				$ 8,964			$ 276,868	$ 18,792
Shares issuable related to our 1% convertible notes	10,745
Income available to Ionis common shareholders, plus assumed conversions	$ 330,439														$ 8,964			$ 276,868	$ 18,792
Shares (Denominator) [Abstract]
Shares used in computing basic net income (loss) per share (in shares)	137,699		137,346		128,712		125,330		124,818		124,370				122,861			132,320	124,016	120,933
Effect of Diluted Securities [Abstract]
Shares issuable related to our ESPP (in shares)	7														60
Shares issuable related to our 1% convertible notes (in shares)	10,260
Shares used in computing diluted net income per share (in shares)	149,856														124,972			134,056	126,098	120,933
1 Percent Convertible Senior Notes [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Interest rate on convertible senior notes	1.00%								1.00%						1.00%			1.00%	1.00%	1.00%
2 3/4 Percent Convertible Senior Notes [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Interest rate on convertible senior notes	2.75%								2.75%						2.75%			2.75%	2.75%	2.75%
Stock Options [Member]
Effect of Diluted Securities [Abstract]
Shares issuable related to stock-based compensation (in shares)	1,254														1,674			1,216	1,619
Restricted Stock Awards [Member]
Effect of Diluted Securities [Abstract]
Shares issuable related to stock-based compensation (in shares)	636														377			514	459
Ionis [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders	$ 372,913		$ 43,226		$ 5,882		$ 18,785		$ 10,510		$ 10,144							$ 440,806	$ 110,776
Akcea [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders	(53,219)		(47,789)		(43,814)		(19,997)		(13,634)		(12,120)							(163,938)	(91,984)
Percentage ownership															100.00%		100.00%			100.00%
Akcea [Member] | Common Stock [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders	$ (53,219)		$ (47,789)		$ (43,814)		$ (19,997)		$ (13,634)		$ (12,063)							$ (163,938)	$ (63,638)
Basic net income (loss) per share (in dollars per share)	$ (0.79)		$ (0.73)		$ (0.72)		$ (0.44)		$ (0.30)		$ (0.33)							$ (2.74)	$ (3.08)
Weighted average shares owned in Akcea (in shares)	67,130		65,538		60,832		45,448		45,448		36,556							59,812	20,669
Akcea [Member] | Preferred Stock [Member]
Quarterly Financial Data (Unaudited) [Abstract]
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders											$ (57)								$ (28,346)
Basic net income (loss) per share (in dollars per share)											$ (0.01)								$ (1.80)
Dividend rate																			6.00%
Conversion ratio																		converted into common stock on a 1:1 basis
Weighted average shares owned in Akcea (in shares)											5,651								15,748

[1] As discussed in Note 1, Organization and Significant Accounting Policies, we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2018 and for the third and fourth quarters of 2017 considered our net income for Ionis on a stand-alone basis plus our share of Akcea's net loss for the period. To calculate the portion of Akcea's net loss attributable to our ownership, we multiplied Akcea's loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.

[2] We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.

[3] Prior to Akcea's IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a six percent cumulative dividend. Upon completion of Akcea's IPO in July 2017, our preferred stock was converted into common stock on a 1:1 basis. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During the three months ended September 30, 2017, Akcea used a two-class method to compute its net income (loss) per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net income (loss) per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea's net income (loss) per share for both Akcea's common and preferred shares that we owned in our calculation of basic and diluted net income (loss) per share for the three months ended September 30, 2017.

[4] For the three months ended December 31, 2018, we had net income available to Ionis common stockholders. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.

[5] For the three months ended March 31, 2017, the calculation excluded the 1 percent and 2.75 percent notes because the effect on diluted earnings per share was anti-dilutive.

[6] For the three months ended March 31, 2017, we owned 100 percent of Akcea. As a result, we did not have to adjust our earnings per share calculation. For the three months ended March 31, 2017, we had net income. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.